The role of cytoskeletal proteins in cardiomyopathies

Current Opinion in Cell Biology

Volumn 10, Issue 1, 1998, Pages 131-139

  Towbin, Jeffrey A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; DYSTROGLYCAN; DYSTROPHIN; IMMUNOGLOBULIN LIGHT CHAIN; MYOSIN HEAVY CHAIN; PROTEIN C; SARCOGLYCAN; TROPOMYOSIN; TROPONIN I; TROPONIN T;

BECKER MUSCULAR DYSTROPHY; CARDIOMYOPATHY; CYTOSKELETON; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; HEART DILATATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MORBIDITY; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; REVIEW;

EID: 0032006681     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80096-3     Document Type: Article

References (68)

1. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstien SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 16:1987;780-789.
2. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 16:1987;844-852.
3. Maron BJ. Hypertrophic cardiomyopathy. of special interest Lancet. 350:1997;127-133 Excellent review of current status of work in HCM, including a clinical overview.
4. Towbin JA. Molecular genetic aspects of cardiomyopathy. Biochem Med Metab Biol. 2492:1993;285-320.
5. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med. 330:1994;930-932.
6. Poetter K, Jiang H, Hassanzadeh S, Master S, Chang A, Dalakas M, Rayment I, Sellers J, Fananapazir L, Esptein N. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. of outstanding interest Nature Genet. 13:1996;63-69 In this paper the authors identify two more genes encoding sarcomeric proteins responsible for a hypertrophic cardiomyopathy (HCM) phenotype. They demonstrate that mutations in genes encoding the essential and regulatory myosin light chains result in an uncommon HCM phenotype characterized by midventricular obstruction.
7. Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, Hiroi S, Sasaoka T, Ohbuchi N, Nakamura T, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. of outstanding interest Nat Genet. 16:1997;379-382 The authors report the identification of mutations of troponin I in patients with hypertrophic cardiomyopathy (HCM), further supporting the claim that familial HCM is a disease of the sarcomere. Importantly, patients with associated Wolff-Parkinson-White (WPW) syndrome were identified in the families studied, thereby showing that WPW is a common feature associated with HCM or that it is genetically hetergeneous as well (see [7]).
8. MacRae C, Ghaisas N, Kass S, Donnelly S, Basson C, Watkins H, Anan R, Thierfelder L, McGarry K, Rowland E, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest. 96:1995;1216-1220.
9. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman CE. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 332:1995;1058-1064.
10. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 326:1992;1108-1114.
11. Geisterfer-Lowrance A, Christe M, Conner D, Ingwall J, Schoen F, Seidman C, Seidman J. A mouse model of familial hypertrophic cardiomyopathy. of outstanding interest Science. 272:1996;731-734 Report of a mouse model of the β-myosin heavy chain (MHC) mutation Arg403→Gln which displays a hypertrophic cardiomyopathy (HCM) phenotype. In this model the mutation was introduced into α-MHC, the predominant MHC isoform in mice. The resultant phenotype, physiologic findings, histologic abnormalities and clinical symptoms were similar to those seen in humans.
12. Sweeney H, Straceski A, Leinwand L, Tikunov B, Faust L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem. 269:1994;1603-1605.
13. Lankford EB, Esptein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing β-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest. 95:1995;1409-1414.
14. Lin D, Bobkova A, Homsher E, Tobachman L. Altered cardiac troponin T in vitro function in the presence of a mutation implication in familial hypertrophic cardiomyopathy. of special interest J Clin Invest. 97:1996;2842-2848 Analysis of the in vitro function of rat cTnT containing the Ile91→Asn mutation found in humans with hypertrophic cardiomyopathy (HCM). The authors describe a 50% increase in the speed of filament movement with this mutation, and they speculate that this change is involved in the underlying HCM phenotype.
15. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J. 14:1995;1952-1960.
16. Farah CS, Reinach FC. The troponin complex and regulation of muscle contraction. FASEB J. 9:1995;755-767.
17. Tohtong R, Yamashita H, Graham M, Haeberle J, Simcox A, Maughan D. Impairment of muscle function caused by mutations of phosphorylation sites in myosin regulatory light chain. Nature. 374:1995;650-653.
18. Keeling PJ, Gang Y, Smith G, Seo H, Bent SE, Murday V, Caforio ALP, McKenna WJ. Familial dilated cardiomyopathy in the United Kingdom. Br Heart J. 73:1995;417-421.
19. Ohlendieck R. Towards an understanding of the dystrophinglycoprotein complex: linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers. Eur J Cell Biol. 69:1996;1-10.
20. Bies RD, Maeda M, Roberds SL, Holder E, Bohlmeyer T, Young JB, Campbell KP. A 5′ dystrophin duplication mutation causes membrane deficiency of α-dystroglycan in a family with X-linked cardiomyopathy. of outstanding interest Am J Hum Genet. 1997; These authors demonstrate that a family with X-linked cardiomyopathy have a 5′ dystrophin gene duplication and associated deficiency of α-dystroglycan This supports earlier suggestions [56] that α-dystroglycan is important in cardiac function.
21. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L, Nigro G, Ventura C, Abbondanza C, Molinari AM, et al. Identification of the Syrian Hamster cardiomyopathy gene. of outstanding interest Hum Mol Genet. 6:1997;601-607 In this paper the authors identify a δ-sarcoglycan mutation as the cause of the Syrian Hamster cardiomyopathy, which is consistent with the hypothesis that cytoskeletal proteins are important in the development of dilated cardiomyopathy.
22. Cox GF, Kunkel LM. Dystrophies and heart disease. of special interest Curr Opin Cardiol. 12:1997;329-343 An excellent up-to-date overview of the association of skeletal myopathy and cardiomyopathy which cytoskeletal proteins.
23. Maeda M, Holder E, Lowes B, Valent S, Bies RD. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. of outstanding interest Circulation. 95:1997;17-20 Demonstration of metavinculin abnormality in a patient with DCM. This is the only case in which metavinculin abnormalities have been found.
24. Bowles KR, Gajarski R, Porter P, Goytia V, Bachinski L, Roberts R, Pignatelli R, Towbin JA. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. of outstanding interest J Clin Invest. 98:1996;1355-1360 This paper reports the mapping of a familial autosomal dominant inherited DCM and mitral valve prolapse phenotype to a locus in the region of chromosome 10 where metavinculin lies.
25. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 50:1987;609-617.
26. Klietsch R, Ervasti JM, Arnold W, Campbell KP, Jorgensen AO. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res. 72:1993;349-360.
27. Ahn AH, Kunkel LM. The structure and functional diversity of dystrophin. Nat Genet. 3:1993;283-291.
28. Koenig Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 53:1988;219-228.
29. Byers TJ, Husain-Chishti A, Dubreuil RR, Branton D, Goldstein LSB. Sequence similarity of the amino-terminal domain of Drosophila beta-spectrin to alpha-actinin and dystrophin. J Cell Biol. 109:1989;1633-1641.
30. Koenig M, Kunkel LM. Dilated analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J Biol Chem. 365:1990;4560-4566.
31. Sadoulet-Puccio HM, Kunkel LM. Dystrophin and its isoforms. of special interest Brain Pathol. 6:1996;25-35 This paper describes the various dystrophin isoforms and their functions.
32. Towbin JA, Hejtmancik JF, Brink P, Gelb BD, Zhu XM, Chamberlain JS, McCabe ERB, Swift M. X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 87:1993;1854-1865.
33. Muntoni F, Cau M, Ganau A, Congiu R, Arvedi G, Mateddu A, Marrosu MG, Cianchetti C, Realdi G, Cao A, Melis MA. Brief report: Deletion of the dystrophin muscle promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med. 329:1993;921-925.
34. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 90:1993;3710-3714.
35. Weller B, Karpati G, Carpenter S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experiential lengthening contractions. J Neurol Sci. 100:1990;9-13.
36. Menke A, Jockusch H. Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature. 349:1991;69-71.
37. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, Freda MP, Miorelli M, Mostacciuolo ML, Fasoli G, et al. Myocardial involvement is very frequent among patients affected with subclinical Beckers muscular dystrophy. of special interest Circulation. 94:1996;3168-3175 In this report, cardiomyopathy is identified as a common feature of BMD, despite the mild skeletal disease associated with BMD.
38. Muntoni F, Melis MA, Ganau A, Dubowitz V. Transcription of the dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked dilated cardiomyopathy. Am J Hum Genet. 56:1995;151-157.
39. Muntoni F, Wilson L, Marrosu G, Marrosu MG, Cianchetti C, Mestroni L, Ganau A, Dubowitz V, Sewry C. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest. 96:1995;693-699.
40. Yoshida K, Ikeda S, Nakamura A, Kagoshima M, Takeda S, Shoji S, Yanagisawa N. Molecular analysis of the Duchenne muscular dystrophy gene in patients with Becker muscular dystrophy presenting with dilated cardiomyopathy. Muscle Nerve. 16:1993;1161-1166.
41. Milasin J, Muntoni F, Severini GM, Bartoloni L, Vatta M, Krajinovic M, Mateddu A, Angelini C, Camerini F, Falaschi A, et al. A point mutation in the 53′ splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy. of outstanding interest Hum Mol Genet. 5:1996;73-79 A novel mutation in the Exon 1-Intron 1 junction of dystrophin a family with XLCM. These findings support the view that the 5′ portion of the dystrophin gene is important in the development of cardiac disease, but suggest that the muscle promoter is not necessarily mutated in patients with XLCM.
42. Ortiz-Lopez R, Li H, Su J, Goytia V, Towbin JA. Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. of outstanding interest Circulation. 95:1997;2434-2440 The authors describe a novel mutation in exon 9 of the dystrophin gene that leads to abnormal secondary structure of the first hinge region of the dystrophin protein (between the amino terminus and rod domains) and the resultant weakening of cardiomyocytes in patients with XCLM. The mutation causes an apparently cardiospecific phenotype.
43. Gurusinghe AD, Wilce MCJ, Austin L, Hearn MTW. Duchenne muscular dystrophy and dystrophin: sequence homology observations. Neorochem Res. 16:1991;681-686.
44. Brenman JE, Chao DS, Xia H, Aldape X, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 82:1995;743-752.
45. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells: caveolin-3 is a component of the sacrolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 271:1996;15150-15165.
46. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature. 338:1989;259-262.
47. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell. 66:1991;1121-1131.
48. Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 122:1993;809-823.
49. Hoffman EP, Clemens PR. HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies. of outstanding interest Curr Opin Rheumatol. 6:1996;528-538 This paper is an excellent review of the current state of knowledge of the function of the DAG complex. It includes reports of mutations in genes encoding the proteins of the dystrophin-associated glycoprotein complex that cause muscular dystrophy.
50. Beckmann JS, Bushby KM. Advances in the molecular genetics of the limb-girdle type of autosomal recessive progressive muscular dystrophy. of outstanding interest Curr Opin Neurol. 5:1996;389-393 An excellent overview of the field.
51. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. of outstanding interest N Engl J Med. 336:1997;618-624 This is the first comprehensive report of the association between DAG mutations and myopathy.
52. McNally EM, Duggan D, Gorospe JR, Bonnemann CG, Fanin M, Pegoraro E, Lidov HG, Noguchi S, Ozawa E, Finkel RS, et al. Mutations that disrupt the carboxy-terminus of γ-sarcoglycan cause muscular dystrophy. of outstanding interest Hum Mol Genet. 5:1996;1841-1842 Identification of γ-sarcoglycan mutations in patients with skeletal myopathy. This is the first report of a γ-sarcoglycan-associated disease.
53. McNally EM, Passos-Bueno MR, Bonnemann CG, Vainzof M, de Sa Moreira E, Lidov HG, Othmane KB, Denton PH, Vance JM, Zatz M, et al. Mild and severe muscular dystrophy caused by a single γ-sarcoglycan mutation. of outstanding interest Am J Hum Genet. 59:1996;1040-1047 This paper reports a mutation in γ-sarcoglycan which causes differing severities of muscular dystrophy, thereby identifying phenotype - genotype stratification of the disease.
54. Bonnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, McNally EM, Duggan DJ, Angelini C, Hoffman EP, et al. β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet. 11:1995;266-273.
55. Lim LE, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V, Meyer J, Richard I, Moomaw C, Slaughter C, et al. β-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet. 11:1995;257-265.
56. 2-chain result in congenital muscular dystrophy, but no cardiac phenotype has been identified. This report has led to speculation that laminin will also be important in the heart, since this protein is important for the function of the muscle membrane.
57. Towbin JA. Biochemical and molecular characterization of X-linked dilated cardiomyopathy (XLCM). Clark EB, Markwald RR, Takao A. Developmental Mechanisms of Heart Disease. 1995;121-132 Futura Publishing Co., Inc. New York.
58. Metzinger L, Blake DJ, Squier MV, Anderson LVB, Deconinck AE, Nawrotzki R, Hilton-Jones D, Davies KE. Dystrobrevin deficiency at the sarcolemma of patients with muscular dystrophy. of outstanding interest Hum Molec Genet. 6:1997;1185-1191 This report reveals that dystrobrevin deficiency can cause muscular dystrophy. No cardiac phenotype has yet been observed, but one is expected to be revealed as more patients with mutations in this gene are identified.
59. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Patter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. Utrophin-dystrophin deficient mice as a model for Duchenne muscular dystrophy. Cell. 90:1997;717-727.
60. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell. 90:1997;729-738.
61. Fadic R, Sunada Y, Waclawik AJ, Buck S, Lewandoski PJ, Campbell KP, Lotz BP. Brief report: deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy. of outstanding interest N Engl J Med. 334:1996;362-366 This report identifies mutations in the DAG complex that lead to cardiac and skeletal muscle disease. It was the first paper to document cardiac dysfunction associated with sarcoglycan protein mutations.
62. McNally EM, Bonnemann CG, Kunkel LM, Bhattacharya SK. Deficiency of adhalin in a patient with muscular dystrophy and cardiomyopathy. of outstanding interest N Engl J Med. 334:1996;1610-1611 A report that identifies mutations in the DAG complex (adhalin) in patients with cardiomyopathy and skeletal myopathy. It supports the speculation that the DAG complex is important for both skeletal muscle and cardiac function.
63. Wang N, Butler JP, Inger DE. Mechanotransduction across the cell surface and through the cytoskeleton. Science. 260:1993;1124-1127.
64. Goncharova EJ, Kam Z, Geiger B. The involvement of adherens junction components in myofibrillogenesis in cultured cardiac myocytes. Development. 114:1992;173-183.
65. Koteliansky VE, Ogryzko EP, Zhidkova NI, Weller PA, Critchley DR, Vancompernolle K, Vanderkerckhove J, Strasser P, Way M, Gimona M, Small JV. An additional exon in the human vinculin gene specifically encodes metavinculin-specific difference peptide. Eur J Biochem. 204:1992;767-772.
66. Belkin AM, Ornatzky OI, Glukhova MA, Koteliansy VE. Immunolocalization of metavinculin in human smooth and cardiac muscles. J Cell Biol. 107:1998;545-553.
67. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 88:1997;393-403.
68. Wang Q, Chen Q, Li H, Towbin JA. Molecular genetics of long QT syndrome: from Genes to patients. Curr Opin Cardiol. 12:1997;310-320.